An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, MD, United States.
2 Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
3 Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
4 Department of Microbiology & Immunology, Weill Cornell Medicine, New York, NY, United States.
1 Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, MD, United States.
2 Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
3 Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
4 Department of Microbiology & Immunology, Weill Cornell Medicine, New York, NY, United States.
Keywords:
Mycobacterium tuberculosis; antimicrobial resistance (AMR); drug discovery; drug resistance; drug synergy; drug tolerance; phenotypic resistance; tuberculosis.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
Editorial on the Research Topic Drug-resistant Mycobacterium tuberculosis
References
Chakaya J., Khan M., Ntoumi F., Aklillu E., Fatima R., Mwaba P., et al. . (2021). Global tuberculosis report 2020 - reflections on the global TB burden, treatment and prevention efforts. Int. J. Infect. Dis. 113 Suppl 1 (Suppl 1), S7–S12. doi: 10.1016/j.ijid.2021.02.107
-
DOI
-
PMC
-
PubMed
Edwards B. D., Field S. K. (2022). The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis. Drugs 82 (18), 1695–1715. doi: 10.1007/s40265-022-01817-w
-
DOI
-
PMC
-
PubMed
Fernandes G. F. S., Thompson A. M., Castagnolo D., Denny W. A., Dos Santos J. L. (2022). Tuberculosis drug discovery: challenges and new horizons. J. Med. Chem. 65 (11), 7489–7531. doi: 10.1021/acs.jmedchem.2c00227
-
DOI
-
PubMed
Nathan C. (2012). Fresh approaches to anti-infective therapies. Sci. Transl. Med. 4 (140), 140sr2. doi: 10.1126/scitranslmed.3003081
-
DOI
-
PMC
-
PubMed
Nathan C. (2017). Kunkel lecture: fundamental immunodeficiency and its correction. J. Exp. Med. 214 (8), 2175–2191. doi: 10.1084/jem.20170637
-
DOI
-
PMC
-
PubMed